Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
about
Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancerState-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PETDual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancerPemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.Measurement of metabolic tumor volume: static versus dynamic FDG scansStability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variabilityEffects of rigid and non-rigid image registration on test-retest variability of quantitative [18F]FDG PET/CT studiesTumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferation and 18F-fluorothymidine uptakeReproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET ImagesA Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT SystemsVariance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settingsTumor quantification in clinical positron emission tomography.Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.Effects of reusing baseline volumes of interest by applying (non-)rigid image registration on positron emission tomography response assessments.Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.Reproducibility and repeatability of same-day two sequential FDG PET/MR and PET/CT.Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting.Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.Longitudinal monitoring of reconstructed activity concentration on a clinical time-of-flight PET/CT scanner.Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer.Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change.Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer.Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'-deoxy-3'-[18F] fluorothymidine in patients with lung cancer.Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.A novel genomic signature predicting FDG uptake in diverse metastatic tumors.An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis.An automatic method for accurate volume delineation of heterogeneous tumors in PET.Comparative assessment of segmentation algorithms for tumor delineation on a test-retest [(11)C]choline dataset.
P2860
Q27025770-CA57ABB2-4508-41CE-B8D0-34ABEDFF124CQ27694674-11F90B84-BD0A-4B5E-B2B8-E8FD28CE83B7Q34465066-49A9F8C5-D03C-43ED-8A33-BA2CE4B8D900Q34744444-5A9A6201-743C-4CA5-A90B-8FB3B5A45928Q35043725-A06AB418-7D3D-4CC3-8635-EFB1C47AA9ABQ35242758-54ABBA7C-9288-4C10-B388-914DD9B99917Q35537570-39630CD8-070A-42BE-A961-B428890436D1Q35660948-A14460DA-2785-40F6-A9A8-FCD818B1157BQ35774813-2C37509D-ECE2-4887-AE69-FC355D006EEAQ35945509-37DA3F71-33C8-40A9-9341-99F0E03A3CF7Q35950812-EE1AE34E-2D7A-469F-908F-AC909A5F9CD4Q36070106-790C4ADB-0797-40A9-9DA7-42D21F0A7812Q36093008-8BC0E02C-4227-4BF0-AB6B-88E32C863E4BQ36162513-0E28EFD1-B489-4C80-BEC3-B768B1B91EAFQ36621641-8E745847-1F67-4E0B-AC86-FBD662A6689AQ36626050-B83DAC84-1407-478F-8671-624B7401609EQ37342658-96C1A1A3-C6D2-4F83-96F6-64EFC7C5F70AQ37474422-062ED18B-77D7-4413-B0FE-390732D4E9FFQ37525550-A2F9F5C3-B9AC-4764-A1FB-6999036C195EQ37600536-E486DC17-EAAC-440C-BB1D-82A2B4303B84Q37638896-EF88E774-D880-4AA1-9AC7-F41267D88068Q37738028-A7DE53DB-54FF-465E-A279-67592C5513D1Q38036127-E724F516-6388-420A-B737-AAB34B9C3977Q38412675-0440B6B0-A133-4877-B340-83E6CC24ADE0Q38766127-33191996-C205-48D9-99A6-BBB5F9C45E30Q39127862-27E7EF07-0E0D-4A1E-8ACE-D0AEFA988E25Q42648185-CBF820A1-F02F-4BF1-B6C1-D42BB02B9205Q43119026-09786D74-F85B-4AA3-A822-744B7333530FQ43608366-B492A1DF-2832-4231-82A9-A763126CD52AQ44021769-0EF12201-39FB-4C51-87DA-CEABB3FC7C1FQ44311665-5246E816-4F3B-4D3E-B58D-78860FCFFB06Q45778912-D0A40973-E09C-4C36-B52E-BF8BC36A65D8Q47103576-2517EC4A-74AE-42FC-AB83-48211C6686C3Q48946602-E4643206-4C72-443B-AEBA-E9CAF37704BAQ49147470-FD87BCEE-6CBC-4F3B-8382-8E7B02DF247CQ49207442-B6F20E93-B4AD-4067-94A7-97D16C9301BFQ49821403-DD877E39-F916-4BFF-9DDD-28948246B640Q49836052-347007A7-C7D6-423C-B525-EC4A74755EC0Q51175504-A9B7FF92-6D88-46E1-A478-723DC2780763Q51289033-A185D33C-A945-4E06-90A2-C27274F01F7B
P2860
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Repeatability of metabolically ...... in non-small cell lung cancer.
@en
Repeatability of metabolically ...... in non-small cell lung cancer.
@nl
type
label
Repeatability of metabolically ...... in non-small cell lung cancer.
@en
Repeatability of metabolically ...... in non-small cell lung cancer.
@nl
prefLabel
Repeatability of metabolically ...... in non-small cell lung cancer.
@en
Repeatability of metabolically ...... in non-small cell lung cancer.
@nl
P2093
P1476
Repeatability of metabolically ...... in non-small cell lung cancer.
@en
P2093
Adrianus J de Langen
Egbert F Smit
Floris H P van Velden
Harm van Tinteren
Otto S Hoekstra
Virginie Frings
P304
P356
10.2967/JNUMED.110.077255
P407
P577
2010-11-15T00:00:00Z